Cargando…
Lipid Metabolism in Late-Onset Alzheimer’s Disease Differs from Patients Presenting with Other Dementia Phenotypes
Abnormal cerebrospinal fluid (CSF) levels of β-amyloid peptides (Aβ(42)) and Tau and cognitive decline are typical characteristics of Alzheimer’s disease (AD). Since dysregulation in lipid metabolism accompanies abnormal amyloid formation, we quantified glycerophospholipids (GP) and sphingolipids (S...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603882/ https://www.ncbi.nlm.nih.gov/pubmed/31195602 http://dx.doi.org/10.3390/ijerph16111995 |
_version_ | 1783431607662673920 |
---|---|
author | Sarrafpour, Syena Ormseth, Cora Chiang, Abby Arakaki, Xianghong Harrington, Michael Fonteh, Alfred |
author_facet | Sarrafpour, Syena Ormseth, Cora Chiang, Abby Arakaki, Xianghong Harrington, Michael Fonteh, Alfred |
author_sort | Sarrafpour, Syena |
collection | PubMed |
description | Abnormal cerebrospinal fluid (CSF) levels of β-amyloid peptides (Aβ(42)) and Tau and cognitive decline are typical characteristics of Alzheimer’s disease (AD). Since dysregulation in lipid metabolism accompanies abnormal amyloid formation, we quantified glycerophospholipids (GP) and sphingolipids (SP) in CSF fractions from participants with late-onset AD (LOAD, n = 29) or with Other Dementia (OD, n = 10) to determine if alterations in lipid metabolism account for pathological differences. Aβ(42) and total Tau levels were determined using a sandwich ELISA. Liposomal-based fluorescent assays were used to measure phospholipase A(2) (PLA(2)) and acid or neutral sphingomyelinase (aSMase, nSMase) activities. Supernatant fluid (SF) and nanoparticle (NP) lipids were quantified using LC-MS/MS. Although CSF Aβ(42) and Tau levels are similar, phosphatidylserine (PS) in SF and ceramide (CM) levels in NP are significantly higher in OD compared with LOAD. The aSMase but not the nSMase activity is higher in OD. PLA(2) activity in CSF from OD subjects positively correlates with several GP classes in SF and NP fractions but not in LOAD fractions. Our data indicate differences in CSF lipid metabolism between dementia variants. Higher levels of inflammatory and apoptotic lipids may induce faster neuronal death, resulting in the earlier cognitive decline in patients with OD phenotypes. |
format | Online Article Text |
id | pubmed-6603882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66038822019-07-17 Lipid Metabolism in Late-Onset Alzheimer’s Disease Differs from Patients Presenting with Other Dementia Phenotypes Sarrafpour, Syena Ormseth, Cora Chiang, Abby Arakaki, Xianghong Harrington, Michael Fonteh, Alfred Int J Environ Res Public Health Article Abnormal cerebrospinal fluid (CSF) levels of β-amyloid peptides (Aβ(42)) and Tau and cognitive decline are typical characteristics of Alzheimer’s disease (AD). Since dysregulation in lipid metabolism accompanies abnormal amyloid formation, we quantified glycerophospholipids (GP) and sphingolipids (SP) in CSF fractions from participants with late-onset AD (LOAD, n = 29) or with Other Dementia (OD, n = 10) to determine if alterations in lipid metabolism account for pathological differences. Aβ(42) and total Tau levels were determined using a sandwich ELISA. Liposomal-based fluorescent assays were used to measure phospholipase A(2) (PLA(2)) and acid or neutral sphingomyelinase (aSMase, nSMase) activities. Supernatant fluid (SF) and nanoparticle (NP) lipids were quantified using LC-MS/MS. Although CSF Aβ(42) and Tau levels are similar, phosphatidylserine (PS) in SF and ceramide (CM) levels in NP are significantly higher in OD compared with LOAD. The aSMase but not the nSMase activity is higher in OD. PLA(2) activity in CSF from OD subjects positively correlates with several GP classes in SF and NP fractions but not in LOAD fractions. Our data indicate differences in CSF lipid metabolism between dementia variants. Higher levels of inflammatory and apoptotic lipids may induce faster neuronal death, resulting in the earlier cognitive decline in patients with OD phenotypes. MDPI 2019-06-05 2019-06 /pmc/articles/PMC6603882/ /pubmed/31195602 http://dx.doi.org/10.3390/ijerph16111995 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sarrafpour, Syena Ormseth, Cora Chiang, Abby Arakaki, Xianghong Harrington, Michael Fonteh, Alfred Lipid Metabolism in Late-Onset Alzheimer’s Disease Differs from Patients Presenting with Other Dementia Phenotypes |
title | Lipid Metabolism in Late-Onset Alzheimer’s Disease Differs from Patients Presenting with Other Dementia Phenotypes |
title_full | Lipid Metabolism in Late-Onset Alzheimer’s Disease Differs from Patients Presenting with Other Dementia Phenotypes |
title_fullStr | Lipid Metabolism in Late-Onset Alzheimer’s Disease Differs from Patients Presenting with Other Dementia Phenotypes |
title_full_unstemmed | Lipid Metabolism in Late-Onset Alzheimer’s Disease Differs from Patients Presenting with Other Dementia Phenotypes |
title_short | Lipid Metabolism in Late-Onset Alzheimer’s Disease Differs from Patients Presenting with Other Dementia Phenotypes |
title_sort | lipid metabolism in late-onset alzheimer’s disease differs from patients presenting with other dementia phenotypes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603882/ https://www.ncbi.nlm.nih.gov/pubmed/31195602 http://dx.doi.org/10.3390/ijerph16111995 |
work_keys_str_mv | AT sarrafpoursyena lipidmetabolisminlateonsetalzheimersdiseasediffersfrompatientspresentingwithotherdementiaphenotypes AT ormsethcora lipidmetabolisminlateonsetalzheimersdiseasediffersfrompatientspresentingwithotherdementiaphenotypes AT chiangabby lipidmetabolisminlateonsetalzheimersdiseasediffersfrompatientspresentingwithotherdementiaphenotypes AT arakakixianghong lipidmetabolisminlateonsetalzheimersdiseasediffersfrompatientspresentingwithotherdementiaphenotypes AT harringtonmichael lipidmetabolisminlateonsetalzheimersdiseasediffersfrompatientspresentingwithotherdementiaphenotypes AT fontehalfred lipidmetabolisminlateonsetalzheimersdiseasediffersfrompatientspresentingwithotherdementiaphenotypes |